Publications by authors named "Claire Givel"
STAT3 mutation-associated airway epithelial defects in Job syndrome.
J Allergy Clin Immunol
August 2023
Background: Job syndrome is a disease of autosomal dominant hyper-IgE syndrome (AD-HIES). Patients harboring STAT3 mutation are particularly prone to airway remodeling and airway infections.
Objectives: Airway epithelial cells play a central role as the first line of defense against pathogenic infection and express high levels of STAT3.
Article Synopsis
- STAT3 deficiency is a rare immunodeficiency that makes patients more prone to infections, particularly pulmonary aspergillosis, and new cases show a rise in azole-resistant infections.
- A study of 13 STAT3-deficient patients revealed that 2 had infections with azole-resistant strains, highlighting a concerning level of resistance in this vulnerable group.
- Treatment options for these patients are complicated, often requiring prolonged antifungal therapies and possibly surgery, emphasizing the need for awareness among healthcare providers about the challenges posed by these resistant infections.
Spectrum of Pulmonary Aspergillosis in Hyper-IgE Syndrome with Autosomal-Dominant STAT3 Deficiency.
J Allergy Clin Immunol Pract
September 2020
Article Synopsis
- STAT3 deficiency in patients increases the risk of recurrent bacterial pneumonia and Aspergillus infections, complicating diagnosis and treatment.
- A study of 74 STAT3-deficient patients revealed 21 cases of pulmonary aspergillosis, mostly affecting those with pre-existing lung conditions like bronchiectasis.
- Despite extended antifungal treatments averaging 13 months, nearly half of the patients experienced relapses, indicating the persistent challenge of managing these infections.
T cell non-Hodgkin lymphomas (T-NHLs) are aggressive malignancies which have a high risk of life-threatening complications. However, their prognosis in the intensive care unit (ICU) setting has not yet been assessed. We conducted a study including 87 ICU patients either with newly diagnosed T-NHLs or those undergoing first-line therapy admitted between January 1, 2000, and December 31, 2014.
View Article and Find Full Text PDF